Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 5, 2011, Pages 675-678

  Brassard, Paul ^a,b,c   Suissa, Samy ^a,c   Kezouh, Abbas ^a   Ernst, Pierre ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Chronic obstructive pulmonary disease; Corticosteroids; Immunosuppressive therapy; Risk; Tuberculosis

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; IPRATROPIUM BROMIDE; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; ZAFIRLUKAST;

ADULT; AGED; ARTICLE; ASTHMA; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; CASE-CONTROL STUDIES; CAUSALITY; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; QUEBEC; RISK; TUBERCULOSIS;

EID: 79952307240     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201007-1099OC     Document Type: Article

References (29)

1. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
2. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-722. (Pubitemid 44330734)
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-S247.
4. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-304.
5. Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundam Clin Pharmacol 2006;20:305-309.
6. Horton DJ, Spector SL. Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol. Chest 1977;71:540-542. (Pubitemid 8081349)
7. Shaikh WA. Pulmonary tuberculosis in patients treated with inhaled beclomethasone. Allergy 1992;47:327-330.
8. Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000;19:215-218. (Pubitemid 30167441)
9. Suzuki K, Tanaka H, Fujishima T, Teramoto S, Kaneko S, Saikai T, Suzuki A, Takahashi Y, Homna H, Sugaya F, et al. [A case of endobronchial tuberculosis associated with bronchial asthma treated with high doses of inhaled corticosteroid]. Nihon Kokyuki Gakkai Zasshi 2001;39:699-704.
10. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of death. 9th Revision ed. Geneva: World Health Organization; 1977.
11. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
12. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83-88. (Pubitemid 38233893)
13. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-1174. (Pubitemid 44914300)
14. Ernst P. Inhaled corticosteroids moderate lung function decline in adults with asthma. Thorax 2006;61:93-94. (Pubitemid 43235420)
15. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther 2010;23:65-70.
16. National Institutes of Health. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics22002. J Allergy Clin Immunol 2002;110:S141-S219.
17. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161:S1-S61.
18. Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm 1986;21:233-241, 258.
19. Schimmer BP, Parker KL. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, Lazo JS, Parker KL, editors. The pharmacological basis of therapeutics, 11th ed. McGraw-Hill; 2006: pp. 1587-1612.
20. Données démographiques régionales: Population selon le groupe d'âge et le sexe, 1996-2009. (Accessed October 15, 2010). Available from: http://www.stat.gouv.qc.ca/donstat/societe/demographie/dons- regnl/regional/index.htm.
21. Clayton DHM. Nested case-control studies. In: Clayton D, Hills M, editors. Statistical models in epidemiology. Oxford: Oxford University Press; 1993: pp. 329-335.
22. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-955. (Pubitemid 29222495)
23. Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 2007;30:477-486. (Pubitemid 350051772)
24. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550. (Pubitemid 19070537)
25. Bieber J, Kavanaugh A. Cigarette smoking, TB, and TNF inhibitors. Ann Rheum Dis 2003;62:1118-1119.
26. Phypers M, Kunimoto D, Behr M, Scholten D, Ellis E. Epidemiology of tuberculosis in Canada. In: Long R, Ellis E, editors. Canadian tuberculosis standards, 6th ed. Ottowa: Public Agency of Canada; 2007: pp. 1-14.
27. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-686.
28. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-805.
29. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elking-Melton M, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784. (Pubitemid 351847559)